Related Experiment Videos
Executive dysfunction predicts nonresponse to fluoxetine in major depression.
J J Dunkin1, A F Leuchter, I A Cook
1Department of Psychiatry and Biobehavioral Sciences, UCLA NPI 37-439 School of Medicine, 760 Westwood Plaza, Los Angeles, CA 90024, USA. jdunkin@mednet.ucla.edu
Journal of Affective Disorders
|August 15, 2000
Summary
Cognitive deficits in executive functioning may predict poor response to fluoxetine in major depression patients. Assessing these functions could help identify individuals likely to benefit from specific antidepressant medications.
Area of Science:
- Neuroscience
- Psychiatry
- Cognitive Psychology
Background:
- Major depression is linked to brain hypometabolism/hypoperfusion in prefrontal cortex and basal ganglia.
- Cognitive deficits, particularly executive dysfunction, are observed in some major depression patients, but reasons for this heterogeneity are unclear.
Purpose of the Study:
- To investigate the relationship between cognitive functioning and treatment outcomes in major depression.
- To explore heterogeneity in treatment response among depressed individuals.
Main Methods:
- Administered a comprehensive neuropsychological test battery to major depression patients before fluoxetine treatment.
- Compared cognitive functioning measures between treatment responders and non-responders.
Main Results:
- No significant differences in age, education, past episodes, or IQ between responders and non-responders.
- Non-responders showed significantly worse pretreatment executive functioning compared to responders, even after controlling for depression severity.
Conclusions:
- Subtle prefrontal dysfunction may predict poor response to certain medications in major depression.
- Executive function assessment could aid in identifying patients likely to respond to specific antidepressant treatments.
- Findings are limited by a small, predominantly female sample, impacting generalizability.